PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 217/22, A61K 31/47

A2

(11) International Publication Number: WO 98/40357

(43) International Publication Date: 17 September 1998 (17.09.98)

(21) International Application Number: PCT/US98/04735

(22) International Filing Date: 12 March 1998 (12.03.98)

(30) Priority Data:
08/815,951 13 March 1997 (13.03.97) US

(71) Applicants *(for all designated States except US)*: AGOURON PHARMACEUTICALS, INC. [US/US]; 10350 North Torrey Pines Road, La Jolla, CA 92037–1020 (US). JAPAN TOBACCO INC. [JP/JP]; 1–1, Murasaki–cho, Takatsuki, Osaka 569 (JP).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: ALBIZATI, Kim, F. [US/US]; 11342 Legacy Terrace, San Diego, CA 92131 (US). REICH, Siegfried [US/US]; 3563 Bancroft Street, San Diego, CA 92104 (US). VARNEY, Michael, D. [US/US]; 7236 Mimosa Drive, Carlsbad, CA 92009 (US). ZHANG, Kanyin, E. [CN/US]; 1956 Oxford Avenue, Cardiff by the Sea, CA 92007 (US). KOBAYASHI, Takuo [JP/JP]; Japan Tobacco Inc., 1–1, Murasaki–cho, Takatsuki, Osaka 569 (JP).

(74) Agents: GARRETT, Arthur, S.; Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC 20005–3315 (US) et al.

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: HIV PROTEASE INHIBITORS

(57) Abstract

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti–viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.